Acurx Pharmaceuticals Files 8-K
Ticker: ACXP · Form: 8-K · Filed: Aug 9, 2024 · CIK: 1736243
Sentiment: neutral
Topics: financial-reporting, operations-update
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on Aug 9th - check for financial updates.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on August 9, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text.
Why It Matters
This 8-K filing indicates Acurx Pharmaceuticals is providing updates on its financial condition and operations to the SEC, which is important for investors to monitor company performance.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting operational and financial information, with no immediate indication of significant negative events.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- August 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text of the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not include the specific details of these results or statements.
When was this 8-K filed with the SEC?
This 8-K was filed on August 9, 2024.
What is the principal business address of Acurx Pharmaceuticals, Inc.?
The principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the SIC code for Acurx Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Acurx Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the Commission File Number for Acurx Pharmaceuticals, Inc.?
The Commission File Number for Acurx Pharmaceuticals, Inc. is 001-40536.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-09 07:13:16
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm2421278d1_8k.htm (8-K) — 24KB
- tm2421278d1_ex99-1.htm (EX-99.1) — 66KB
- 0001104659-24-087545.txt ( ) — 269KB
- acxp-20240809.xsd (EX-101.SCH) — 3KB
- acxp-20240809_lab.xml (EX-101.LAB) — 33KB
- acxp-20240809_pre.xml (EX-101.PRE) — 22KB
- tm2421278d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On August 9, 2024, Acurx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the second quarter ended June 30, 2024 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated August 9, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: August 9, 2024 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer